Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases

被引:12
作者
Auner, HW
Zebisch, A
Ofner, P
Sill, H
Linkesch, W
Krause, R
机构
[1] Med Univ, Div Hematol, A-8036 Graz, Austria
[2] Med Univ, Inst Med Informat Stat & Documentat, A-8036 Graz, Austria
[3] Med Univ, Dept Med, A-8036 Graz, Austria
[4] Univ London Imperial Coll Sci & Technol, MRC, Ctr Clin Sci, London W12 ONN, England
关键词
autologous stem cell transplantation; high-dose chemotherapy; infection; risk factor;
D O I
10.1007/s00277-005-1025-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of risk factors for the occurrence of neutropaenic fever after haematopoietic stem cell transplantation (HSCT) have been proposed. We were interested in whether these factors remain valid for several early infection-related outcomes when applied to a homogeneous group of patients in uni- and multivariate analyses. Therefore, we analysed 144 consecutive patients with lymphoproliferative disorders receiving autologous peripheral blood HSCT. Variables tested as potential risk factors for the occurrence of fever, documented infection (DI), microbiologically documented infection (MDI) or failure of first-line antimicrobial therapy were sex, conditioning regimen, prolonged neutropaenia, low number of CD34+ cells transplanted, purging, lack of selective gut decontamination, higher age and increased body mass index. In uni- and multivariate analyses, conditioning including total body irradiation was the only risk factor for the occurrence of fever, and neutropaenia >= 10 days was the only factor associated with failure of first-line antimicrobial therapy. None of the variables tested was associated with an increased risk for DI or MDI. This analysis suggests that a number of previously proposed risk factors actually are of minor clinical relevance for early infections in the majority of patients receiving autologous HSCT.
引用
收藏
页码:532 / 537
页数:6
相关论文
共 34 条
[1]   CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders:: High purging efficiency but increased risk of severe infections [J].
Altès, A ;
Sierra, J ;
Esteve, J ;
Martin-Henao, G ;
Marín, P ;
Sureda, A ;
Briones, J ;
Martino, R ;
Villamor, N ;
Colomer, D ;
Carreras, E ;
Garcia, J ;
Brunet, S ;
Montserrat, E .
EXPERIMENTAL HEMATOLOGY, 2002, 30 (07) :824-830
[2]   Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma [J].
Auner, HW ;
Sill, H ;
Mulabecirovic, A ;
Linkesch, W ;
Krause, R .
ANNALS OF HEMATOLOGY, 2002, 81 (07) :374-377
[3]   Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation -: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) [J].
Bertz, H ;
Auner, HW ;
Weissinger, F ;
Salwender, HJ ;
Einsele, H ;
Egerer, G ;
Sandherr, M ;
Schüttrumpf, S ;
Südhoff, T ;
Maschmeyer, G .
ANNALS OF HEMATOLOGY, 2003, 82 (Suppl 2) :S167-S174
[4]   HEMATOPOIETIC RESCUE AFTER HIGH-DOSE CHEMOTHERAPY USING AUTOLOGOUS PERIPHERAL-BLOOD PROGENITOR CELLS OR BONE-MARROW - A RANDOMIZED COMPARISON [J].
BEYER, J ;
SCHWELLA, N ;
ZINGSEM, J ;
STROHSCHEER, I ;
SCHWANER, I ;
OETTLE, H ;
SERKE, S ;
HUHN, D ;
SIEGERT, W .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1328-1335
[5]  
Buzyn A., 1999, Clin Microbiol Infect, V5, P449, DOI 10.1111/j.1469-0691.1999.tb00174.x
[6]   Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies [J].
Çelebi, H ;
Akan, H ;
Akçaglayan, E ;
Üstün, C ;
Arat, M .
BONE MARROW TRANSPLANTATION, 2000, 26 (02) :211-214
[7]   Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation [J].
Chen, CS ;
Boeckh, M ;
Seidel, K ;
Clark, JG ;
Kansu, E ;
Madtes, DK ;
Wagner, JL ;
Witherspoon, RP ;
Anasetti, C ;
Appelbaum, FR ;
Bensinger, WI ;
Deeg, HJ ;
Martin, PJ ;
Sanders, JE ;
Storb, R ;
Storek, J ;
Wade, J ;
Siadak, M ;
Flowers, MED ;
Sullivan, KM .
BONE MARROW TRANSPLANTATION, 2003, 32 (05) :515-522
[8]  
D'Amico S, 2003, SIXTEENTH CENT J, V34, P480
[9]   A randomized, multicenter study of G-CSF starting on day+1 vs day+5 after autologous peripheral blood progenitor cell transplantation [J].
de Azevedo, AM ;
Nucci, M ;
Maiolino, A ;
Vigorito, AC ;
Simoes, BP ;
Aranha, FJP ;
Tabak, DG ;
Voltarelli, J ;
de Souza, C .
BONE MARROW TRANSPLANTATION, 2002, 29 (09) :745-751
[10]   Hemopoietic recovery and infectious complications in breast cancer and multiple myeloma after autologous CD34+ cell-selected peripheral blood progenitor cell transplantation [J].
De Rosa, L ;
Anghel, G ;
Pandolfi, A ;
Riccardi, M ;
Amodeo, R ;
Majolino, I .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 79 (01) :85-91